Kestra Private Wealth Services’s AbCellera Biologics ABCL Stock Holding History

Kestra Private Wealth Services’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$91.8K	Sell	11,700 -1,000	-8%	-$4.89K	﹤0.01%	1747
2026 Q1	$44.3K	Hold	12,700	–	–	﹤0.01%	1715
2025 Q4	$43.4K	Buy	12,700 +900	+8%	+$4.02K	﹤0.01%	1687
2025 Q3	$59.4K	Sell	11,800 -800	-6%	-$3.53K	﹤0.01%	1629
2025 Q2	$43.2K	Hold	12,600	–	–	﹤0.01%	1579
2025 Q1	$28.1K	Hold	12,600	–	–	﹤0.01%	1487
2024 Q4	$36.9K	Buy	12,600 +1,600	+15%	+$4.46K	﹤0.01%	1401
2024 Q3	$28.6K	Buy	+11,000	New	+$30.5K	﹤0.01%	1344

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Kestra Private Wealth Services's ABCL Position: Q2 2026 in Review

Kestra Private Wealth Services reduced its AbCellera Biologics (ABCL) stake by 7.9% in Q2 2026, selling an estimated $4.89K and leaving 11,700 shares worth $91.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1747.

Kestra Private Wealth Services first reported a position in ABCL in Q3 2024 and has held it in 8 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Kestra Private Wealth Services held 11,700 shares of AbCellera Biologics worth $91.8K as of Q2 2026.
Kestra Private Wealth Services sold 1,000 AbCellera Biologics shares in Q2 2026, an estimated $4.89K.
AbCellera Biologics made up ﹤0.01% of Kestra Private Wealth Services's portfolio in Q2 2026, its #1747 holding.
Kestra Private Wealth Services first reported a position in AbCellera Biologics in Q3 2024 and has held it in 8 quarters since.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Kestra Private Wealth Services's 13F filing for Q2 2026, filed 28 Jul 2026.